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Abstract
A 54-year-old female living in Europe pre-
sented with gait ataxia, dizziness, and bilateral
hearing loss. Magnetic resonance imaging
(MRI) revealed non-specific white matter
changes. The patient’s condition gradually
deteriorated over two years without diagnosis.
The patient continued to decline cognitively
and neurologically with worsening ataxia and
upper motor neuron signs. Repeat MRI showed
worsening white matter changes. Lumbar
puncture, not previously done, showed positive
Lyme testing. Treatment with intravenous cef-
triaxone resulted in marked neurological
improvement. Four years after symptom, the
patient has short-term memory deficits and
chronic fatigue, but is otherwise neurological-
ly, cognitively, and functionally intact. Follow
up MRI findings remain largely unchanged.
Because cases of intraparenchymal or
encephalopathic neuroborreliosis in America
are lacking, so are treatment options. We pres-
ent a rare case and discuss our experience
with antibiotic treatment. This case lends evi-
dence to define optimal treatment of this dis-
ease, imperative for hastening neurological
recovery.
Introduction
Lyme neuroborreliosis (LNB) is an infec-
tious disorder of the nervous system caused by
tick-borne spirochetes of the Borrelia burgdor-
feri sensu lato complex. It can commonly start
with a bull’s eye rash (erythema migrans) and
can systemically spread, causing arthritis,
heart block, and effects in both the central and
peripheral nervous systems.1 In Europe, LNB is
most often caused by B. garinii, less frequently
by B. afzelii, and rarely by B. burgdorferi sensu
stricto (which is predominantly in North
America).2 Borrelia subspecies are thus
responsible for significant differences in the
clinical presentations of LNB observed in
North America and Europe. Early LNB can
cause lymphocytic meningitis; involvement of
cranial and peripheral nerves is reported to
occur in 5-15% of untreated patients.2 Late
LNB, which is considerably rarer, can involve
brain/spinal cord parenchymal inflammation.2,3
There are important clinical consequences
of these different species and their geographic
distributions, possibly as a result of differen-
tial species pathogenicity, as illustrated in one
study.4 Neuroborreliosis is the most common
disseminated infection of Lyme disease in
Europe, but is infrequently reported in the
United States. Furthermore, even though all
three aforementioned subspecies exist in
Europe, the same study notes that the North
American-predominant subspecies (B.
burgdorferi sensu stricto) is responsible for
only 8-11% of neuroborreliosis cases in
Europe.4 Thus, this could explain the fact that
reports of neuroborreliosis reported in the US
(particularly with encephalopathy, for
instance) are rare, especially in the adult pop-
ulation. As a result, optimal treatment regi-
mens of central nervous system (CNS)
parenchymal neuroborreliosis are incomplete,
according to the American Academy of
Neurology (AAN).3 The present case describes
a patient with chronic Lyme neuroborreliosis;
potentially adding much-needed evidence on
effective management of this rare but serious
disease.
Case Report
A 54-year-old Caucasian female with past
medical history of uncomplicated migraines
first noticed dizziness and ataxic gait in April
2009. The woman, American by nationality,
was living with her husband in the
Netherlands at the time. Shortly thereafter,
she developed bilateral hearing loss and
noticed a 20-pound unintentional weight loss
over the previous couple months. She was
admitted to a hospital in the Netherlands,
where reportedly blood work, electroen-
cephalography (EEG), and echocardiogram
were normal. Magnetic resonance imaging
(MRI) at the time apparently showed nonspe-
cific white matter changes present over both
cerebral hemispheres. The patient remained
relatively stable until her next episode that
occurred in April 2011. A new, sudden-onset
gait imbalance triggered further workup.
Though magnetic resonance angiography
(MRA) was normal, MRI was initially read as
being suspicious of an apparent small, acute
non-hemorrhagic stroke in the left cerebellar
peduncle as well as progressive white matter
changes (on a reviewed re-read, it was not
read as a stroke). EEG showed sharp waves
over the left temporal lobe but no foci of epilep-
tiform activity. Her workup was otherwise
unrevealing; it included complete blood count,
basic metabolic panel, creatine phosphoki-
nase, lactate, echocardiogram with bubble
study, chest radiograph, vasculitis and hyper-
coagulable profiles. At that time, she was start-
ed on aspirin 81 mg daily as well as levetirac-
etam 250 mg twice daily.
The patient was then referred to our facility
for neurological evaluation. The patient report-
ed subjective generalized weakness/fatigue,
but denied any fevers, rash, joint pains, swal-
lowing difficulty, or visual problems. She had
no family history of any neurological disorders.
Her examination revealed slowed speech,
bilateral decrease in hearing, and bilateral
non-sustained nystagmus on horizontal gaze.
She was alert and oriented times three, but
had poor cognition and insight into her dis-
ease history. Bilateral dysmetria, ataxic gait,
hyperreflexia with nonsustained clonus and
bilateral Babinski reflexes were also found on
exam. Repeat brain MRI at our facility (Figure
1) showed relatively unchanged scattered
round-oval hyperintensities in the subcortical
and periventricular white matter, as well as
cerebellum and pons. Spinal MRI did not show
any lesions. B12 level was low-normal at 242
pg/mL (normal range 200-900), for which she
was empirically started on weekly subcuta-
neous B12 injections (1000 mcg) to make sure
B12 levels did not drop and potentially com-
                                                    Infectious Disease Reports 2014; volume 6:5496
Correspondence: Mohamed H. Yassin, University
of Pittsburgh Medical Center, Mercy Hospital,
10550 Ermire Building, 1400 Locust Street,
Pittsburgh, PA 15219, USA.
Tel.: +1.412.232.7798 - Fax: +1.412.232.3292.
E-mail: yassinm@upmc.edu
Key words: Lyme neuroborreliosis, Borrelia
burgdorferi, encephalopathy.
Contributions: VV and MR analyzed data and
patient records, obtained references, prepared
figures and table, and overall wrote the manu-
script; MZ and MHY supervised the aforemen-
tioned and took care of the patient in this case
report in an inpatient and outpatient setting.
Conflict of interests: the authors declare no
potential conflict of interest.
Received for publication: 21 July 2014.
Revision received: 30 September 2014.
Accepted for publication: 30 September 2014.
This work is licensed under a Creative Commons
Attribution NonCommercial 3.0 License (CC BY-
NC 3.0).
©Copyright V. Verma et al., 2014
Licensee PAGEPress, Italy











[page 52]                                                      [Infectious Disease Reports 2014; 6:5496]
pound symptoms. Lumbar puncture (LP) done
at that time revealed normal opening pressure
with 200 white blood cells (65% monocytes,
35% neutrophils), zero red blood cells, low glu-
cose level of 11 (serum level 107), and elevated
protein 324 mg/dl (normal range 15-45). 
The patient was admitted to the hospital and
the infectious diseases service was consulted.
Repeat LP two days post-admission showed
similar results (yellow-colored fluid, 229 white
blood cells (55% monocytes, 45% neutrophils),
12 red blood cells, glucose 14, protein 290).
Autoimmune workup was negative for antinu-
clear antibody, antineutrophil cytoplasmic
antibody, rheumatoid factor; angiotensin-con-
verting enzyme, aldolase, erythrocyte sedimen-
tation rate, and C-reactive protein levels were
normal. Antibodies to cardiolipin, myeloperox-
idase-3, proteinase-3, Sjogren-A/B, and para-
neoplastic antibodies against neuronal nuclei
and Purkinje cells anti-neuronal nuclear anti-
body (ANNA), and Purkinje cell cytoplasmic
antibody (PCCA) were negative. Infectious dis-
eases workup that was negative is listed in
Table 1.  Screening cerebrospinal fluid (CSF)
enzyme-linked immunosorbent assay (ELISA)
for Lyme disease was positive at 4.42 (refer-
ence range <1.1). A confirmatory Western blot
subsequently revealed positive bands at 18, 23,
41, and 58 kDa. Though antibodies were
detected in the CSF, polymerase chain reaction
(PCR) for Lyme DNA in CSF was negative
times two. The overall CSF immunoglobulin
(IgG) level was elevated to 65.6 (reference
range 0.8 to 7.7), as was the IgG index (0.89,
normal <0.6) with oligoclonal bands. CSF
myelin basic protein was normal, however. All
CSF cultures for bacteria (including mycobac-
teria) and fungi remained negative. 
On review of these results, the patient was
diagnosed with LNB. IV ceftriaxone 2 g daily was
administered via a peripherally inserted intra-
venous catheter (PICC) for 28 days. The patient
finished her course of ceftriaxone and followed
up as outpatient with both Neurology and
Infectious Diseases. After her antibiotic course,
the patient noted complete resolution of her atax-
ia, dizziness, hearing loss, and improvement of
weakness/fatigue. Levetiracetam was stopped in
March 2012. At the time of last follow-up (March
2013), almost four years after initial symptoms,
the patient’s only reported symptoms were chron-
ic fatigue (much improved relative to before
antibiotics started), and some impairment in for-
mation of short-term memories. On exam, she
does display 0/3 word recall at five minutes, slight-
ly decreased fine motor coordination, and is
slightly hyperreflexic (albeit markedly less so
compared to initial exam). Otherwise she
remains neurologically, cognitively, and function-
ally intact. Follow up brain MRI showed slight
decrease in size of the pontine and cerebellar
peduncular lesions, but otherwise no changes
(Figure 2).
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Table 1. Negative infectious disease workup in this patient.
1                      Herpes simplex virus-1 and -2 PCR, CSF
2                      Epstein-Barr virus PCR, CSF
3                      Cytomegalovirus PCR, CSF
4                      Mycobacterial stain and culture, CSF
5                      Syphilis, CSF
6                      Cryptococcus antigen, CSF
7                      Histoplasma antigen, urine
8                      HIV ELISA, serum
9                      West Nile virus serology, CSF
10                    Lymphocytic choriomeningitis virus serology, CSF
11                    Coxsackievirus serology panel, CSF
12                    Measles serology, CSF
13                    Mumps serology, CSF
14                    St. Louis encephalitis serology, CSF
15                    Eastern/Western equine encephalitis serology, CSF
16                    California encephalitis serology, CSF
17                    Echovirus serology, CSF
18                    Adenovirus serology, CSF
19                    Influenza A/B antibody testing, nasopharyngeal swab
PCR, polymerase chain reaction; CSF, cerebrospinal fluid.
Figure 1. Fluid-attenuated inversion recovery - fast spin echo sequence images of the
patient’s brain on initial presentation to our hospital. Lesions are present in the periven-
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Discussion
The present patient was probably infected
with a European-specific species of Borrelia
(B. garinii or B. afzelii); although European in
origin, this case adds data to the overall data
that is reported in the United States. Though
the causative agent was not specifically geno-
typed, it would not have changed clinical man-
agement diagnostically nor therapeutically.
On radiological review, the main item on the
differential diagnosis of the patient’s MRI
lesions, and certainly more common in North
America, included demyelinating conditions.
Hence, multiple sclerosis (MS) should be at
the forefront of a differential diagnosis of sim-
ilar brain lesions, as should other infectious
causes (e.g., syphilis and other infectious
causes in Table 1). Vitamin B12 deficiency and
autoimmune conditions such as systemic
lupus erythematosus are important to consid-
er, as well as the rare but frequently missed
acute disseminated encephalomyelitis.5
In this patient, the main distinction that
needed to be made was LNB versus MS.
Though oligoclonal bands were present on CSF
analysis as well, it has been well established
that this is an expected finding in LNB.6 The
patient had a negative CSF myelin basic pro-
tein level, which is a relatively specific marker
for MS.7 Additionally, the CSF measles/mumps
antibody titer was not elevated, which is a reli-
able indicator of differentiating LNB from
MS.8,9 In our case CSF Lyme DNA PCR was neg-
ative, which is a common finding in chronic
neuroborreliosis; detection by PCR or CSF cul-
ture occurs in only 10-30% of patients.2,10
Furthermore, radiologic findings in this
patient are not typical of MS lesions.11 The vast
majority of MS cases have at least one
ovoid/round and well-demarcated lesion, and
periventricular lesions are often perpendicular
to the ventricles (Dawson’s fingers); this
patient’s lesions were radiologically irregular
with ragged borders and ill-defined margins.
Moreover, two prominent lesions in this
patient (in the cerebellar peduncle and pons)
differ from MS lesions that are largely around
CSF/ventricular flow. Most importantly, the
patient’s clinical status vastly and rapidly
improved within weeks of IV antibiotic therapy
without any relapse or new symptoms at two
year follow up.9 Chronically progressing neuro-
logical symptoms that disappeared without
exacerbation after antibiotic use (no corticos-
teroids or newer anti-inflammatory MS agents
were used) further points to LNB over MS.
Overall, a salient point to glean from this clin-
ical diagnostic process is that often in clinical
medicine, some items on the differential diag-
nosis can never be fully excluded (e.g. recur-
rent or multiphasic disseminated
encephalomyelitis), but based on a constella-
tion of many diverse supporting factors (in
this patient, multiple laboratory tests, clinical
picture, radiology, and treatment course), a
principal diagnosis can indeed be reached.
Diagnosis in this patient was highly sus-
pected based the presence of intrathecal anti-
Borrelia antibodies. In accordance with both
the European Federation of Neurological
Societies and the AAN, the gold standard of
LNB diagnosis involves intrathecal anti-
Borrelia antibodies together with the clinical
patient picture.9,12 Though serum Lyme serolo-
gy was not checked due to initial suspicion for
MS, both aforementioned guidelines endorse
that clinically diagnosing LNB is essential. The
patient’s rapid and relapse-free improvement
for two years after IV ceftriaxone further sup-
ports the diagnosis. Additionally, it was uncer-
tain why hypoglycorrhachia was present,
which is atypical of LNB, but it could possibly
be related to the relatively long duration of the
illness in this patient before the diagnosis was
made.
At the time of follow-up, neither Lyme serol-
ogy nor repeat lumbar puncture for monitoring
intrathecal antibodies was done. These have
been shown to be of relatively lower yield as
follow-up measures because they can be per-
sistently elevated for years after treatment,
irrespective of symptomatic remission.13,14
Recent research, however, has helped to iden-
tify biomarkers such as CXCL13 with high sen-
sitivity and specificity to identify acute LNB as
well as monitor during follow-up.15 This is
especially important in rare cases without
intrathecal antibody production to cement a
diagnosis without perpetuating neurological
symptoms. Though further work will need to be
done, novel biomarkers remain intriguing
options as diagnostic aids for this disease.
It is also noteworthy that at most recent (2
year) follow-up, the patient’s MRI signals have
not changed for the most part (only the signal
abnormalities in the pons and cerebellar
peduncle improved). More importantly, as long
as the patient’s clinical status is (and
remains) improved and nearly intact, this is in
our opinion of little consequence. It could be
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Figure 2. Fluid-attenuated inversion recovery - conventional spin echo sequence images
of the patient’s brain at two-year follow-up. Lesions persist in the periventricular areas
and white matter (A,B), but show decreased signal in the pons (C) and middle cerebellar
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possible that because this patient had chronic
disease, and/or the nature of the infection, the
lesions may never change despite the patient
being clinically normal. Indeed, there are radi-
ology reports that support this notion, includ-
ing one with a five-year follow-up.16
This case supports the use of parenteral
antibiotics to treat this patient, since the
patient had an excellent clinical response with
2 g IV ceftriaxone. In terms of antibiotic thera-
py, our treatment is consistent with recom-
mendations from the Infectious Diseases
Society of America and the AAN, though the
latter report mentions that there is a dearth of
supportive data for cases involving the CNS
parenchyma.3,17 Though we continued
Levetiracetam for seizure prophylaxis in this
patient, we did not use corticosteroids; it is
apparent that more research needs to be done
on this issue, although the AAN hints that
there may be no major impact of using corti-
costeroids.3 To prevent future cases of delayed
diagnosis while the patient has continuing
neurological symptoms, it is important for cli-
nicians to keep Lyme disease on the differen-
tial diagnosis of any lingering neurological
symptoms. This pathogen, possibly depending
on the strain, can be very difficult to clear by
the immune system. Indeed, animal studies
have showed that if Borrelia can survive the
initial innate immune response, there are very
few barriers to developing long-term infection
within distant tissues such as the brain.18
Clinically, this means Lyme disease should be
high on a lingering neurological disease differ-
ential diagnosis.
Lastly, in patients with documented history
of LNB, there are salient complications for cli-
nicians to regularly monitor, which this patient
displayed as well. As many as 15% of patients
can experience chronic symptoms (such as
fatigue, depression, memory or concentration
defects, and musculoskeletal pain) which can
occur years after completion of therapy,
despite positive clinical response to initial
antibiotic therapy.10,19 Unfortunately, these
symptoms do not respond to additional antibi-
otics, so their administration is largely not
warranted; management is best done sympto-
matically and with gentle reassurance/counsel-
ing.10 It is also important for physicians to not
completely ignore recurrence of Lyme-specific
symptoms (such as erythema migrans),
because a small proportion of patients develop
recurrent Lyme disease, which is thought to be
due to reinfection with a different strain
rather than relapse from the previous strain.20
These cases would be managed with repeat
antibiotics; management would be as if the
patient were Lyme-naïve. 
Conclusions
The present case serves to show that a
patient presenting with many neurological
deficits not localized to one area must be
investigated thoroughly to rule out rare dis-
eases such as LNB. In suspected cases, though
data is greatly lacking in the USA, doing a
prompt and deep investigation (also ruling out
other causes on the differential diagnosis such
as multiple sclerosis) is important to provide
early treatment for the patient instead of caus-
ing lingering and possibly additive neurologi-
cal deficits. Once diagnosed, however, our
experience shows that parenteral antibiotic
treatment works quite effectively for near-com-
plete resolution of clinical symptoms, regard-
less of the predictable persistence of radiologic
findings.
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